• Title/Summary/Keyword: DW2282

Search Result 2, Processing Time 0.012 seconds

In Vivo Antitumor Activities and Pharmacokinetics of DW2282 Depending on Vehicles (DW2282의 용매의존성 항암효과 및 약동력학)

  • Moon, Eun-Yi;Choi, Chung-Ha;Seong, Seung-Kyoo;Lee, Jin;Ryu, Jei-Man;Lee, Moon-Sun;Jung, Sang-Hun;Chung, Yong-Ho;Lee, Dog-Keun;Yoon, Sung-June
    • Biomolecules & Therapeutics
    • /
    • v.6 no.4
    • /
    • pp.395-399
    • /
    • 1998
  • DW2282, (S)- (+)-4-phenyl -1-[N-(4-am mob enzoyl) -indolin-5- sulfonyl]-4,5- dihydro-2-imidazolone hydrochloride, is a novel anticancer agent thought to have an unique mechanism of action on the inhibition of tumor growth. In this study, we estimated in vivo antitumor activities and pharmacokinetics of Dw2282 depending on various vehicles. The inhibition rate of tumor growth was increased by 50, 100 and 200 mg/kg of Dw2282 in a dose-dependent manner. When Dw2282 dissolved in 4 sorts of vehicles was orally single dosed to rats at 50 mg/kg, Cmax of Dw2282 in 0.5% CMC.Na was a half as high as those in PG, PG+CP and PG+CP+DW. When Dw2282 was orally administered to mice for 5 days, antitumor activity of 130 mg/kg suspended in 0.5% CMC.Na was as effective as that of 65 mg/kg dissolved in the rest of vehicles. Taken together, it is thought that antitumor activities of Dw2282 are resulted from the absorption extent of it and related to the vehicle used.

  • PDF

Effect of DW282 on the Induction of Methemoglobinemia, Hypoglycemia or WBC Count and Hematological Changes

  • Moon, Eun-Yi;Hwang, Hyun-Sook;Choi, Chung-Ha;Jung, Sang-Hun;Yoon, Sung-June
    • Archives of Pharmacal Research
    • /
    • v.22 no.6
    • /
    • pp.565-570
    • /
    • 1999
  • DW2282,(S)-(+)-4-phenyl-1-[1-(4-aminobenzoyl)-indoline-5-sulfonyl]-4,5-dihydro-2-imidazolone hydrochloride, is a new anticancer agent which is thought to exhibit a characteristic mechanism of action in the inhibition of tumor growth. In this study, we estimated the toxicities of DW2282 in mice. When mice were orally dosed for five consecutive days at the dosages of 50, 100 and 150 mg/kg, DW2282 did not induced methemoglobinemia and hypoglycemia at any of these doses. However, increased ALT and AST values were observed in the 150 mg/kg dosing group, and white blood cells (WBC) were significantly decreased at all doses. However, the changes in WBC count, ALT and AST immediately reversed after the cessation of drug administration. In addition, we found that DW2282 did not cause an increase in hemolysis in human blood. Taken together, these data suggested that DW2282 may have a relatively low level of toxicity, and that there may be a quick recovery from any toxicity it dose produce.

  • PDF